These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 23297801

  • 1. Novel 3-substituted rimonabant analogues lack Δ(9) -tetrahydrocannabinol-like abuse-related behavioural effects in mice.
    Walentiny D, Vann R, Mahadevan A, Kottani R, Gujjar R, Wiley J.
    Br J Pharmacol; 2013 May; 169(1):10-20. PubMed ID: 23297801
    [Abstract] [Full Text] [Related]

  • 2. Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR.
    Psychopharmacology (Berl); 2009 Apr; 203(2):219-28. PubMed ID: 18592221
    [Abstract] [Full Text] [Related]

  • 3. JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys.
    Ginsburg BC, Schulze DR, Hruba L, McMahon LR.
    J Pharmacol Exp Ther; 2012 Jan; 340(1):37-45. PubMed ID: 21965552
    [Abstract] [Full Text] [Related]

  • 4. Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle.
    Wiley JL, Matthew Walentiny D, Vann RE, Baskfield CY.
    Behav Pharmacol; 2011 Sep; 22(5-6):480-8. PubMed ID: 21712709
    [Abstract] [Full Text] [Related]

  • 5. Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.
    McMahon LR.
    Br J Pharmacol; 2011 Mar; 162(5):1060-73. PubMed ID: 21091643
    [Abstract] [Full Text] [Related]

  • 6. Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice.
    Vann RE, Warner JA, Bushell K, Huffman JW, Martin BR, Wiley JL.
    Eur J Pharmacol; 2009 Aug 01; 615(1-3):102-7. PubMed ID: 19470387
    [Abstract] [Full Text] [Related]

  • 7. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
    Stewart JL, McMahon LR.
    J Pharmacol Exp Ther; 2010 Jul 01; 334(1):347-56. PubMed ID: 20375197
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
    Walentiny DM, Vann RE, Wiley JL.
    Neuropharmacology; 2015 Jun 01; 93():237-42. PubMed ID: 25698527
    [Abstract] [Full Text] [Related]

  • 10. Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys.
    Schulze DR, Carroll FI, McMahon LR.
    Psychopharmacology (Berl); 2012 Aug 01; 222(3):425-38. PubMed ID: 22374253
    [Abstract] [Full Text] [Related]

  • 11. Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats.
    Gatch MB, Forster MJ.
    Psychopharmacology (Berl); 2018 Mar 01; 235(3):673-680. PubMed ID: 29138877
    [Abstract] [Full Text] [Related]

  • 12. Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats.
    Järbe TU, Gifford RS, Makriyannis A.
    Eur J Pharmacol; 2010 Dec 01; 648(1-3):133-8. PubMed ID: 20854804
    [Abstract] [Full Text] [Related]

  • 13. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    McMahon LR.
    Psychopharmacology (Berl); 2006 Oct 01; 188(3):306-14. PubMed ID: 16953389
    [Abstract] [Full Text] [Related]

  • 14. Assessment of dependence potential and abuse liability of Δ8-tetrahydrocannabinol in mice.
    Vanegas SO, Reck AM, Rodriguez CE, Marusich JA, Yassin O, Sotzing G, Wiley JL, Kinsey SG.
    Drug Alcohol Depend; 2022 Nov 01; 240():109640. PubMed ID: 36179506
    [Abstract] [Full Text] [Related]

  • 15. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.
    Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH, Selley DE, Lichtman AH, Sim-Selley LJ.
    Neuropsychopharmacology; 2010 Jul 01; 35(8):1775-87. PubMed ID: 20357755
    [Abstract] [Full Text] [Related]

  • 16. Cannabimimetic properties of ajulemic acid.
    Vann RE, Cook CD, Martin BR, Wiley JL.
    J Pharmacol Exp Ther; 2007 Feb 01; 320(2):678-86. PubMed ID: 17105826
    [Abstract] [Full Text] [Related]

  • 17. Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys.
    Hruba L, McMahon LR.
    J Pharmacol Exp Ther; 2017 Aug 01; 362(2):278-286. PubMed ID: 28533288
    [Abstract] [Full Text] [Related]

  • 18. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
    Wiley JL, Selley DE, Wang P, Kottani R, Gadthula S, Mahadeven A.
    J Pharmacol Exp Ther; 2012 Feb 01; 340(2):433-44. PubMed ID: 22085649
    [Abstract] [Full Text] [Related]

  • 19. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR.
    J Pharmacol Exp Ther; 2006 Dec 01; 319(3):1211-8. PubMed ID: 16943255
    [Abstract] [Full Text] [Related]

  • 20. Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
    Järbe TU, Li C, Vadivel SK, Makriyannis A.
    Psychopharmacology (Berl); 2008 Jul 01; 198(4):467-78. PubMed ID: 18264696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.